| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Modified Organism
Pexa-Vec Vaccine
Record information and status
Record ID
111973
Status
Published
Date of creation
2017-05-31 17:05 UTC (dina.abdelhakim@cbd.int)
Date of publication
2017-05-31 17:05 UTC (dina.abdelhakim@cbd.int)

Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name
Pexa-Vec Vaccine
Transformation event
JX-594
Developer(s)
Sillagen
11th Floor, HP bldg
83 Uisadang-daero, Yeongdeungpo-gu
Seoul
Republic of Korea
Phone:+82 (2) 368-2600
Url:SILLAGEN
Description
Pexa-Vec (Pexastimogene Devacirepvec) is a live-attenuated vaccinia virus that is is designed to target and destroy cancer cells. Multiple mechanisms of action for Pexa-Vec have been demonstrated in preclinical models and patients: 1) tumor cell infection and lysis, 2) antitumor immune response induction, and 3) tumor vascular disruption.

The recipient organism was modified to disrupt the endogenous thymidine kinase gene with the insertion of the coding sequence for each of human granulocyte macrophage-colony stimulating factor, and β-galactosidase enzyme.
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Vaccinia virus - Poxvirus, Smallpox vaccine, VACV, VV, Vaccinia
Characteristics of the transformation process
Vector
pSC65
Techniques used for the modification
  • Homologous Recombination
Introduced or modified genetic elements
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
Granulocyte macrophage-colony stimulating factor gene - Homo sapiens - HUMAN
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Beta-galactosidase gene - Escherichia coli - ECOLX
Selectable marker genes and reporter genes
Early/Late promoter
P7.5 early/late promoter - Vaccinia virus - Poxvirus, Smallpox vaccine, VACV, VV, Vaccinia
Notes regarding the genetic elements introduced or modified in this LMO
The pSC65 plasmid contining the GM-CSF gene was transfected by calcium phosphate precipitation into CV-1 monkey kidney cells that had been infected 2 hours previously with a low multiplicity of non-recombinant virus. The plasmid is designed to facilitate homologous recombination into the vaccinia thymidine kinase gene. This recombination event renders the endogenous thymidine kinase gene inactive which leads to viral replication being dependent on the high cellular thymidine kinase activity that is a hallmark of cancer cells.
LMO characteristics
Modified traits
Common use(s)
  • Pharmaceutical

Records referencing this document (2)
IDDescription
2record(s) found
Country's Decision or any other Communication1 record
Risk Assessment1 record